These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19521678)

  • 1. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.
    Walter H; Kammerer H; Frasch K; Spitzer M; Abler B
    Psychopharmacology (Berl); 2009 Sep; 206(1):121-32. PubMed ID: 19521678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients.
    Nielsen MØ; Rostrup E; Wulff S; Bak N; Lublin H; Kapur S; Glenthøj B
    Biol Psychiatry; 2012 May; 71(10):898-905. PubMed ID: 22418013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study.
    Abler B; Erk S; Walter H
    Psychopharmacology (Berl); 2007 Apr; 191(3):823-33. PubMed ID: 17265148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.
    Juckel G; Schlagenhauf F; Koslowski M; Filonov D; Wüstenberg T; Villringer A; Knutson B; Kienast T; Gallinat J; Wrase J; Heinz A
    Psychopharmacology (Berl); 2006 Aug; 187(2):222-8. PubMed ID: 16721614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.
    Schlagenhauf F; Juckel G; Koslowski M; Kahnt T; Knutson B; Dembler T; Kienast T; Gallinat J; Wrase J; Heinz A
    Psychopharmacology (Berl); 2008 Mar; 196(4):673-84. PubMed ID: 18097655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment.
    Snitz BE; MacDonald A; Cohen JD; Cho RY; Becker T; Carter CS
    Am J Psychiatry; 2005 Dec; 162(12):2322-9. PubMed ID: 16330597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the reward system by antipsychotic treatment.
    Juckel G
    Dialogues Clin Neurosci; 2016 Mar; 18(1):109-14. PubMed ID: 27069385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperresponsivity and impaired prefrontal control of the mesolimbic reward system in schizophrenia.
    Richter A; Petrovic A; Diekhof EK; Trost S; Wolter S; Gruber O
    J Psychiatr Res; 2015 Dec; 71():8-15. PubMed ID: 26522867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.
    Bertolino A; Caforio G; Blasi G; De Candia M; Latorre V; Petruzzella V; Altamura M; Nappi G; Papa S; Callicott JH; Mattay VS; Bellomo A; Scarabino T; Weinberger DR; Nardini M
    Am J Psychiatry; 2004 Oct; 161(10):1798-805. PubMed ID: 15465976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients.
    Kirsch P; Ronshausen S; Mier D; Gallhofer B
    Pharmacopsychiatry; 2007 Sep; 40(5):196-8. PubMed ID: 17874350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.
    da Silva Alves F; Bakker G; Schmitz N; Abeling N; Hasler G; van der Meer J; Nederveen A; de Haan L; Linszen D; van Amelsvoort T
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1577-86. PubMed ID: 23978392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
    Bédard AM; Maheux J; Lévesque D; Samaha AN
    Schizophr Bull; 2013 May; 39(3):692-702. PubMed ID: 22927669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study.
    Knolle F; Ermakova AO; Justicia A; Fletcher PC; Bunzeck N; Düzel E; Murray GK
    Transl Psychiatry; 2018 Sep; 8(1):196. PubMed ID: 30242202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.
    Blasi G; Popolizio T; Taurisano P; Caforio G; Romano R; Di Giorgio A; Sambataro F; Rubino V; Latorre V; Lo Bianco L; Fazio L; Nardini M; Weinberger DR; Bertolino A
    Psychiatry Res; 2009 Jul; 173(1):31-8. PubMed ID: 19428222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia.
    Dowd EC; Barch DM
    PLoS One; 2012; 7(5):e35622. PubMed ID: 22574121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia.
    Prata DP; Mechelli A; Picchioni MM; Fu CH; Toulopoulou T; Bramon E; Walshe M; Murray RM; Collier DA; McGuire P
    Arch Gen Psychiatry; 2009 Nov; 66(11):1162-72. PubMed ID: 19884604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.
    Kumari V; Ettinger U; Lee SE; Deuschl C; Anilkumar AP; Schmechtig A; Corr PJ; Ffytche DH; Williams SC
    Psychopharmacology (Berl); 2015 Sep; 232(17):3135-47. PubMed ID: 25980483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
    Müller JL; Deuticke C; Putzhammer A; Röder CH; Hajak G; Winkler J
    Psychiatry Clin Neurosci; 2003 Dec; 57(6):562-8. PubMed ID: 14629703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.